EU Panel Backs Frontline Atezolizumab Regimen in NSCLC

February 1, 2019 – The European Medicine’s Agency Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer (NSCLC). For patients with EGFR or ALK molecular abnormalities, the 4-drug regimen should be indicated only after progression on appropriate … (leggi tutto)